HWI group

The HWI group is an innovative and independent partner of the pharma, medtech and biotech industries. Today we offer our services for active ingredients, medical devices and associated products at our sites in Rülzheim and Frankfurt (HWI pharma services GmbH), Appenweier (HWI development GmbH) and Planegg (HWI regulatory services GmbH).

Development and validation

We develop and validate test methods for identity testing, assay, purity testing and in vitro dissolution for active ingredients, excipients, intermediates, ready-to-use products and medical devices in accordance with international regulatory requirements and the latest scientific and technical knowledge.

Quality control

In our GMP- and FDA-certified laboratory we conduct analytical testing as part of batch release for active ingredients, medicinal products and drug-related medical devices. We can undertake all your stability testing: storage, analytical testing and stability report as part of ICH studies and follow-up studies.

Development

The active ingredient is at the heart of our risk-based formulation development. Its properties have a critical influence on the quality of the product. In our ultra-modern clean rooms we can also work with highly potent active ingredients. By using statistical design of experiment (DoE) we offer an efficient pharmaceutical development that completely fulfils the requirements of quality by design.

Drug development

News

News

Stay up-to-date. In our news section we regularly inform you about the latest news from HWI group.

25. November 2021

We are proud to present our new SEM-EDX system

SEM-EDX combines high-resolution imaging with elemental identification in a spatial manner.

28. September 2021

HWI blog: The way of process digitalisation in pharmacovigilance

HWI group is being completely digitalised ICSR processing in pharmacovigilance. What are the main advantages of a digital process flow and how does low-code / no-code help to digitalise complex processes in an interdisciplinary setting? Get all the answers in our HWI-blog by Dr Lisa Held and Thomas Wessling

14. June 2021

Coronavirus measures of the HWI group

Until further notice, the HWI group will take the following measures to ensure that our services are maintained for you.

Click on "Read more" and read the measures in detail.

11. May 2021

#Mediathek

Video -> Drug Development

Have a look: In our video you get an overview of our services in drug development

Mediathek

HWI blog: Troubleshooting

Unexpected quality problems in pharmaceutical manufacturing require a reliable root cause analysis as well as quality and safety assessment followed by the definition of preventive measures to avoid such incidents.

Find out what this means in detail in our HWI-blog by Dr Sandra Huertgen.

30 years HWI

30 years ago: On January 8^th, 1991, the company was founded by Dr. Stefan Wissel and Prof. Dr. Hanns Häberlein. The two university friends created the name HWI from the first letters of their last names.

Expansion of the Management Team

As of January 1^st, 2021, Dr Frank Böttcher will be appointed to the management team of HWI pharma services GmbH and will strengthen the current management team of Dr Stefan Wissel and Dr Melanie Kerst.

You will find further information in our press release.

18. December 2020

Merry Christmas & Happy New Year 2021

At the end of the year we look back on eventful, challenging and extraordinary months. Therefore, we would like to thank you very much for the good and successful cooperation with you!